TRIALSITEIQ PUBLIC FEASIBILITY SCORECARD · GRADE C

NCT07230483: An Open-Label, Multicenter Study to Evaluate Long-Term Safety and Efficacy of CM512 in Atopic Dermatitis Patients.

Sponsor: Keymed Biosciences Co.Ltd · Phase: PHASE2 · Area: DERMATOLOGY_AESTHETIC · Target Enrollment: 246 pts

Competing Trials Overlap

2 Active Trials

Excess Burn Exposure

$8,256,000

Rescue Site Savings

+$5,443,800

Unlock Full NCT07230483 Backup Super-Site Packet ($49 One-Time Pass)

Download the complete list of top-decile low-cannibalization clinical sites, verified Principal Investigator (PI) direct emails/phones, and protocol optimization benchmarks.

Download $49 NCT07230483 Rescue Dossier →